Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer

Predicting drug response offers an opportunity to improve cancer treatment delivery. Recently, microdevices were invented to ascertain in vivo drug response but have not yet been evaluated for pancreatic cancer. This study is a prospective phase 1 safety study of intraoperative placement and retrieval of a microdevice in patients with pancreatic cancer. The devices will be implanted intra-operatively and removed en-bloc with the tumor after a 4- hour incubation period. Patients will be monitored to ensure that the placement and retrieval of these devices does not increase complication rates wi

Trial Details

NCT ID
NCT07254091
Phase
EARLY_PHASE1
Sponsor
Northwell Health
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Device Arm with Therapeutic Agents
Locations (sample)
  • New Hyde Park, New York, United States|40.7351,-73.68791

Key Eligibility Criteria

  • Patients must be at least or greater than18 years old
  • All sexes, genders, races, and ethnic groups are eligible for this trial
  • Patients with a suspicious or histologically confirmed pancreatic lesion for which surgery is indicated for either diagnostic or therapeutic purpos…
  • Patients must be a candidate for pancreatoduodenectomy or pancreatectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →